Drug intelligence / Profile preview

4P FSH

Development stage: Preclinical
Lead developer: Nutriband
Modality: Recombinant Proteins and Enzymes, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
Administration: Transdermal

Overview

4P FSH is a transdermal formulation of follicle-stimulating hormone (FSH) being developed by 4P Therapeutics, a subsidiary of Nutriband. It utilizes a proprietary transdermal delivery system (patch) to deliver FSH, a biologic hormone, as an alternative to traditional subcutaneous or intramuscular injections. The drug's mechanism of action involves the activation of the follicle-stimulating hormone receptor (FSHR), which in turn stimulates follicular development in women and spermatogenesis in men. This product is intended for the treatment of infertility and is currently in the preclinical stage of development.

Other names: follicle stimulating hormoneFSHfollicle stimulating hormone-Nutriband

Targets

FSHR (Follicle-stimulating hormone receptor)

Beyond the preview

Go deeper on 4P FSH.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4P FSH.